Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €152.13 EUR
Change Today +3.74 / 2.52%
Volume 961.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 1:28 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1040 Spring Street

Silver Spring, MD 20910

United States

Phone: 301-608-9292

Fax: 301-608-9291

ineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The company is also developing technologies to increase the supply of donated lungs through ex-vivo perfusion of donor lungs prior to transplant. Sales and Distribution Distribution of Remodulin, Tyvaso and Orenitram: The company distributes Remodulin, Tyvaso and Orenitram throughout the United States and Puerto Rico through two contracted specialty pharmaceutical distributors: Accredo Health Group, Inc. (Accredo) and CVS Caremark (Caremark). These specialty pharmaceutical distributors are responsible for assisting patients with obtaining reimbursement for the cost of its treprostinil-based products and providing other support services. United States Distribution of Adcirca: The company sells Adcirca to pharmaceutical wholesalers. Under its manufacturing and supply agreement with Eli Lilly and Company (Lilly), Lilly manufactures Adcirca and distributes it via its wholesaler network, which includes Accredo and Caremark, in the same manner that it distributes its own pharmaceutical products. International Distribution of Remodulin: The company sells subcutaneous and intravenous Remodulin outside the United States to various distributors, each of which has exclusive distribution rights in one or more countries within Europe, Israel and the Middle East, Asia and South and Central America. The company also distributes Remodulin in Canada through a specialty pharmaceutical wholesaler. In some of the European markets where the company is not licensed to market Remodulin, such as Spain and the United Kingdom, the company sells Remodulin on a named-patient basis in which therapies are approved for individual patients by a national medical review board, hospital or health plan on a case-by-case basis. Research and Development The company’s research and development expenses, as of December 31, 2014, totaled approximately $242.5 million. Customers Accredo Health Group, Inc. accounted for 58 percent of the company’s revenues, as of December 31, 2014. History United Therapeutics Corporation was founded in 1996. The company was incorporated in Delaware in 1996.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €152.13 EUR +3.74

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.144.50 CHF +2.90
Alexion Pharmaceuticals Inc $203.55 USD +5.45
Celanese Corp $64.13 USD +2.09
Nippon Shinyaku Co Ltd ¥4,035 JPY +105.00
Vertex Pharmaceuticals Inc $128.30 USD +5.07
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 46.1x
Price/Sales 5.8x
Price/Book 7.0x
Price/Cash Flow 41.2x
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.